BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 22853
Title: PPAR receptors at the crossroad of obesity, diabetes, and pancreatic cancer
Reviewer's code: 03442462
Reviewer's country: China
Science editor: Ya-Juan Ma
Date sent for review: 2015-09-29 17:11
Date reviewed: 2015-11-19 22:50

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[ ] Minor revision
[ ] Grade E: Poor		[Y] No	[Y] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is a review of PPARγ. The author concluded that PPAR receptors at the crossroad of obesity, diabetes, and pancreatic cancer. PPARγ agonists may be used to treat insulin-resistance, obesity, obesity-associated inflammation, desmoplastic reaction and PDAC. However, the author discussed so many details about PDAC which could described briefly. There is no information about PPARγ when I read the text to page 10. For the last decades, the effects of PPARγ activity on tumor biology have been studied intensely. There are two reviews of PPARγ and pancreatic cancer[1,2]. The author should choose different sides to review the PPARγ. So, it has new information in this review. reference [1] Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy? Curr Cancer Drug Targets. 2013 May;13(4):460-71. [2] Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta. 2014 Jan;1845(1):42-52.